Medios AG, a leading provider of Specialty Pharma in Europe, has announced the appointment of Katrin Neuffer as Director Investor Relations & Communications, effective immediately. Neuffer, who holds a degree in business administration and has around 20 years of experience in capital markets communications, will oversee the company's communications with investors, analysts, the media, and the public. She succeeds Claudia Nickolaus, who is handing over leadership of the department.
Neuffer's career includes a decade at SDAX-listed Wacker Neuson SE, where she served as Head of Investor Relations & Corporate Communications from 2007 to 2018, guiding the company from its IPO to becoming a consistently attractive investment. She also led the Strategy and Sustainability departments there. Subsequently, she held the position of Vice President Investor Relations & Corporate Communications and Marketing at Exyte Group (formerly M+W Group), where she managed an international team of 20 and was responsible for preparing an IPO with a target market capitalization exceeding EUR 2 billion. Since 2020, she has worked as an independent consultant for publicly listed companies in areas such as investor relations, IPO preparation, and crisis and restructuring communications.
Claudia Nickolaus played a key role in building and shaping Medios' Investor Relations activities, from financial reporting and ESG communications to the company's first Capital Markets Day in 2022. Prior to joining Medios, she held senior investor relations positions at publicly listed companies, including Merck KGaA. Thomas Meier, CEO of Medios AG, expressed his gratitude: "With Katrin Neuffer, we are gaining a proven capital markets expert who has guided publicly listed companies through decisive phases of development, from IPOs to strategic repositioning. Her experience will help us reposition Medios in the capital markets and intensify our dialogue with investors, analysts, and the media. On behalf of the Company, I would like to express my sincere thanks to Claudia Nickolaus: Over many years, she shaped Medios' capital markets communications with tremendous dedication, a high level of professionalism, and personal reliability. She deserves our sincere gratitude for this."
The appointment comes as Medios prepares for key financial events in the 2026 fiscal year, including the Half-Year Financial Report on August 12, participation in the Berenberg and Goldman Sachs 15th German Corporate Conference from September 21 to 23 in Munich, the Medios Capital Markets Day on September 28/29, and the Quarterly Statement as of September 30 on November 10. These events will be critical for the company to communicate its strategic direction and performance to the investment community.
Medios AG is Germany's first listed specialty pharmaceutical company, listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and included in the SDAX selection index. The company operates in Germany, the Netherlands, Belgium, and Spain, focusing on pioneering individualized medicine to make innovative therapies available to a broader population. With Neuffer's expertise, Medios aims to strengthen its capital market presence and foster transparent dialogue with its stakeholders. More information about Medios can be found at www.medios.group, and details on individualized medicine are available at https://app.medios.group/en/individualizedmedicine.
